Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
BackgroundThe GTPase superfamily: a conserved switch for diverse cell functions
Bourne, H. R., Sanders, D. A., & McCormick, F. (1990) · Nature · doi:10.1038/348125a0 · Cited by 2,333
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundPhosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954 · cited 1×
“Ras–GTP also binds the catalytic subunit of type I PI3K”
BackgroundRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Proteins regulating Ras and its relatives
Boguski, M. S., & McCormick, F. (1993) · Nature · doi:10.1038/366643a0 · Cited by 1,901 · cited 1×
“Ras signalling Ras proteins are small GTPases that cycle between inactive guanosine diphosphate (GDP)-bound and active guanosine triphosphate (GTP)-bound conformations (Ras–GDP and Ras–GTP, respectively”
BackgroundThe Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875 · cited 1×
“Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism.”
BackgroundMutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733 · cited 1×
“PTPN11 was identified as the causative gene in ∼50% of Noonan syndrome cases through a positional cloning and candidate gene approac”
BackgroundHigh frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730 · cited 1×
“The V600E mutation is also detected in a large percentage of nevi, which are benign skin lesions of melanocytes that are thought to be senescen”
BackgroundInducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641 · cited 1×
“In Mx1 – Cre mice, Cre recombinase is under control of the Mx1 promoter, which drives high-level expression in haematopoietic cells and some other tissues in response to interfero”
BackgroundThe Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,267
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundA Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211 · cited 1×
“These changes impair the intrinsic GTPase activity and confer resistance to GAPs, thereby causing cancer-associated mutant Ras proteins to accumulate in the active, GTP-bound conformatio”
BackgroundSomatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 1×
“In an elegant series of experiments, strains of mice were created that express an oncogenic Kras G12D or Kras G12V allele from the endogenous Kras locu”
BackgroundThe neurofibromatosis type 1 gene encodes a protein related to GAP
Xu, G., O'Connell, P., Viskochil, D., Cawthon, R., Robertson, M., Culver, M., Dunn, D., Stevens, J., Gesteland, R., White, R., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90024-9 · Cited by 1,095
Cawthon, R. M., Weiss, R., Xu, G., Viskochil, D., Culver, M., Stevens, J., Robertson, M., Dunn, D., Gesteland, R., O'Connell, P., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90253-b · Cited by 1,094
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
Viskochil, D., Buchberg, A. M., Xu, G., Cawthon, R. M., Stevens, J., Wolff, R. K., Culver, M., Carey, J. C., Copeland, N. G., Jenkins, N. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90252-a · Cited by 1,082
Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003) · Nature Genetics · doi:10.1038/ng1156 · Cited by 1,033
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
BackgroundThe GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
Martin, G. A., Viskoohil, D., Bollag, G., McCabe, P. C., Crosier, W. J., Haubruck, H., Conroy, L., Clark, R., O'Connell, P., Cawthon, R. M., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90150-d · Cited by 982 · cited 1×
“Subsequent biochemical analysis demonstrated potent Ras GAP activit”
BackgroundSelf-citationTraverse, S., Gomez, N., Paterson, H., Marshall, C., & Cohen, P. (1992) · Biochemical Journal · doi:10.1042/bj2880351 · Cited by 874
The structural basis of the activation of Ras by Sos
Boriack-Sjodin, P. A., Margarit, S. M., Bar-Sagi, D., & Kuriyan, J. (1998) · Nature · doi:10.1038/28548 · Cited by 799
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798 · cited 1×
“PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-triphosphate, which activates downstream kinases such as 3-phosphoinositide-dependent protein kinase 1 ( PDK1 ) and Ak”
BackgroundTuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Self-citationGermline mutations in HRAS proto-oncogene cause Costello syndrome
Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, M., Kato, K., Suzuki, Y., Kure, S., et al. (2005) · Nature Genetics · doi:10.1038/ng1641 · Cited by 679
Multiple ras functions can contribute to mammalian cell transformation
White, M. A., Nicolette, C., Minden, A., Polverino, A., Aelst, L. V., Karin, M., & Wigler, M. H. (1995) · Cell · doi:10.1016/0092-8674(95)90507-3 · Cited by 649
Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment
Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K., & Parada, L. F. (2002) · Science · doi:10.1126/science.1068452 · Cited by 633
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.
Gibbs, J. B., Sigal, I. S., Poe, M., & Scolnick, E. M. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.18.5704 · Cited by 609
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., et al. (2007) · Nature Genetics · doi:10.1038/ng1926 · Cited by 605
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 602
NF1 Tumor Suppressor Gene Function
Cichowski, K., & Jacks, T. (2001) · Cell · doi:10.1016/s0092-8674(01)00245-8 · Cited by 601
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cavé, H., Verloes, A., Okamoto, N., Hennekam, R. C. M., Gillessen-Kaesbach, G., Wieczorek, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1749 · Cited by 599
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome
Tartaglia, M., Pennacchio, L. A., Zhao, C., Yadav, K. K., Fodale, V., Sarkozy, A., Pandit, B., Oishi, K., Martinelli, S., Schackwitz, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1939 · Cited by 586
Biological properties of human c-Ha-ras1 genes mutated at codon 12
Seeburg, P. H., Colby, W. W., Capon, D. J., Goeddel, D. V., & Levinson, A. D. (1984) · Nature · doi:10.1038/312071a0 · Cited by 585
Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome
Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., McCormick, F., & Rauen, K. A. (2006) · Science · doi:10.1126/science.1124642 · Cited by 571
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context
Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., & Barbacid, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00191-0 · Cited by 571 · cited 1×
“In an elegant series of experiments, strains of mice were created that express an oncogenic Kras G12D or Kras G12V allele from the endogenous Kras locu”
BackgroundK-ras is an essential gene in the mouse with partial functional overlap with N-ras
Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 545
Biological and biochemical properties of human rasH genes mutated at codon 61
Der, C. J., Finkel, T., & Cooper, G. M. (1986) · Cell · doi:10.1016/0092-8674(86)90495-2 · Cited by 543 · cited 1×
“Glutamine 61 is essential for GTP hydrolysis, and substituting any amino acid at this position except glutamic acid blocks hydrolysi”
MethodGTP-dependent segregation of H-ras from lipid rafts is required for biological activity
Prior, I. A., Harding, A., Yan, J., Sluimer, J., Parton, R. G., & Hancock, J. F. (2001) · Nature Cell Biology · doi:10.1038/35070050 · Cited by 518 · cited 1×
“HRAS is associated with cholesterol-rich regions on the plasma membrane known as lipid rafts, whereas KRAS is distributed throughout the plasma membran”
BackgroundBentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481 · cited 1×
“In addition, mice that express endogenous levels of Braf V600E develop benign lung tumours that rarely progress to adenocarcinoma and show features of senescenc”
BackgroundMargarit, S. M., Sondermann, H., Hall, B. E., Nagar, B., Hoelz, A., Pirruccello, M., Bar-Sagi, D., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00149-1 · Cited by 480 · cited 1×
“Therefore, these mutant SOS1 proteins are thought to enable the increased access of Ras to the catalytic site, thereby increasing the rate of guanine nucleotide exchang”
BackgroundPlowman, S. J., Muncke, C., Parton, R. G., & Hancock, J. F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504114102 · Cited by 468 · cited 1×
“However, in more recent studies, computational analysis and immunogold electron microscopy suggest that oncogenic HRAS and KRAS proteins are recruited to small (10–12 nm), dynamic clusters in the inner plasma membrane, referred to as nanocluster”
BackgroundBivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467 · cited 1×
“KRAS can return to endomembrane compartments following phosphorylation of the hypervariable regio”
BackgroundShp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment
Zhang, S. Q., Yang, W., Kontaridis, M. I., Bivona, T. G., Wen, G., Araki, T., Luo, J., Thompson, J. A., Schraven, B. L., Philips, M. R., et al. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00050-4 · Cited by 447 · cited 1×
“Finally, the inactivation of the negative regulatory CSK pathway has also been proposed to mediate SHP2-dependent Ras activatio”
BackgroundDistinct requirements for Ras oncogenesis in human versus mouse cells
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M. (2002) · Genes & Development · doi:10.1101/gad.993902 · Cited by 431
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Loh, M. L. (2004) · Blood · doi:10.1182/blood-2003-09-3287 · Cited by 427
Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A., et al. (2004) · Nature Medicine · doi:10.1038/nm1084 · Cited by 420
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., van der Burgt, I., Palleschi, A., Petrucci, T. C., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499925 · Cited by 415
Signaling Interplay in Ras Superfamily Function
Mitin, N., Rossman, K. L., & Der, C. J. (2005) · Current Biology · doi:10.1016/j.cub.2005.07.010 · Cited by 399 · cited 1×
“GTP-bound Ras can interact productively with more than 20 effectors, including Raf, phosphatidylinositol 3-kinase ( PI3K ) and Ral guanine nucleotide-dissociation stimulator ( RALGDS ), to regulate various cellular responses including proliferation, survival and differentiatio”
BackgroundCOMPARTMENTALIZED RAS/MAPK SIGNALING
Mor, A., & Philips, M. R. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090723 · Cited by 398 · cited 1×
“Specific Ras proteins are processed differently and therefore follow distinct trafficking pathway”
BackgroundProtein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras.
Bennett, A. M., Tang, T. L., Sugimoto, S., Walsh, C. T., & Neel, B. G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7335 · Cited by 397 · cited 1×
“Upon cytokine or growth-factor binding, SHP2 binds directly to some receptors, such as the platelet-derived growth-factor receptor ( PDGFR ), and associates with various adaptor proteins including growth-factor-receptor bound protein 2 ( GRB2 ), fibro-blast growth-factor-receptor substrate, insulin-receptor substrate…”
BackgroundcDNA cloning of the type 1 neurofibromatosis gene: Complete sequence of the NF1 gene product
Marchuk, D. A., Saulino, A. M., Tavakkol, R., Swaroop, M., Wallace, M. R., Andersen, L. B., Mitchell, A. L., Gutmann, D. H., Boguski, M., & Collins, F. S. (1991) · Genomics · doi:10.1016/0888-7543(91)90017-9 · Cited by 389
Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours
Malliri, A., van der Kammen, R. A., Clark, K., van der Valk, M., Michiels, F., & Collard, J. G. (2002) · Nature · doi:10.1038/nature00848 · Cited by 384 · cited 1×
“PI3K also activates Rac, a Rho family GTPase, which has been shown to be important for transformation by oncogenic Ras in some cellular context”
BackgroundStimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RAS
Joneson, T., White, M. A., Wigler, M. H., & Bar-Sagi, D. (1996) · Science · doi:10.1126/science.271.5250.810 · Cited by 371
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G.-S. (2007) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 371
Phospholipase Cepsilon: a novel Ras effector
Kelley, G. G. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.743 · Cited by 361
Activation of RalA is critical for Ras-induced tumorigenesis of human cells
Lim, K.-H., Baines, A. T., Fiordalisi, J. J., Shipitsin, M., Feig, L. A., Cox, A. D., Der, C. J., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.030 · Cited by 355
K-Ras is essential for the development of the mouse embryo
Koera, K., Nakamura, K., Nakao, K., Miyoshi, J., Toyoshima, K., Hatta, T., Otani, H., Aiba, A., & Katsuki, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201284 · Cited by 355
NOONAN SYNDROME AND RELATED DISORDERS: Genetics and Pathogenesis
Tartaglia, M., & Gelb, B. D. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162305 · Cited by 355
Khosravi-Far, R., White, M. A., Westwick, J. K., Solski, P. A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M. H., & Der, C. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3923 · Cited by 343
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513068200 · Cited by 338
Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism
Lambert, J. M., Lambert, Q. T., Reuther, G. W., Malliri, A., Siderovski, D. P., Sondek, J., Collard, J. G., & Der, C. J. (2002) · Nature Cell Biology · doi:10.1038/ncb833 · Cited by 326 · cited 1×
“Ras–GTP directly binds to the Rac exchange factor tumour invasion and metastasis inducing protein 1 ( TIAM1 ), leading to increased levels of Rac and subsequent actin reorganizatio”
BackgroundSignal transduction and the Ets family of transcription factors
Yordy, J. S., & Muise-Helmericks, R. C. (2000) · Oncogene · doi:10.1038/sj.onc.1204036 · Cited by 325 · cited 1×
“ERK kinases can phosphorylate both cytosolic and nuclear substrates, which include transcription factors such as JUN and ELK1 , which is an E26 transformation-specific sequence (ETS) family member that forms part of the serum response factor that regulates FOS expressio”
BackgroundTHE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS
Gibbs, J. B., & Oliff, A. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.143 · Cited by 324
Gorlin, R. J. (1969) · American Journal of Diseases of Children · doi:10.1001/archpedi.1969.02100030654006 · Cited by 323
Regulation of a Novel Human Phospholipase C, PLCε, through Membrane Targeting by Ras
Song, C., Hu, C.-D., Masago, M., Kariya, K.-I., Yamawaki-Kataoka, Y., Shibatohge, M., Wu, D., Satoh, T., & Kataoka, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008324200 · Cited by 320 · cited 1×
“Phospholipase Ce also binds directly to Ras–GTP, and the consequent hydrolysis of PIP2 to diacylglycerol and inositol-1,4,5-triphosphate serves to release calcium and activate protein kinase”
BackgroundStructural Analysis of Autoinhibition in the Ras Activator Son of Sevenless
Sondermann, H., Soisson, S. M., Boykevisch, S., Yang, S.-S., Bar-Sagi, D., & Kuriyan, J. (2004) · Cell · doi:10.1016/j.cell.2004.10.005 · Cited by 311 · cited 1×
“Therefore, these mutant SOS1 proteins are thought to enable the increased access of Ras to the catalytic site, thereby increasing the rate of guanine nucleotide exchang”
BackgroundRas and Rho regulation of the cell cycle and oncogenesis
Pruitt, K., & Der, C. J. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00528-6 · Cited by 311 · cited 1×
“Activation of these transcriptional regulators can lead to the expression of proteins that control cell-cycle progression, such as cyclin”
BackgroundMolecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling
Agazie, Y. M., & Hayman, M. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7875-7886.2003 · Cited by 306 · cited 1×
“One involves a p120GAP docking site on growth-factor receptors or adaptors such as Gab; by dephosphorylating such sites, SHP2 prevents the membrane localization of p120GAP, therefore preventing the downregulation of Ra”
BackgroundDevelopmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1
Li, Z., Godinho, F. J., Klusmann, J.-H., Garriga-Canut, M., Yu, C., & Orkin, S. H. (2005) · Nature Genetics · doi:10.1038/ng1566 · Cited by 305
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 300 · cited 1×
“GTP-bound Ras can interact productively with more than 20 effectors, including Raf, phosphatidylinositol 3-kinase ( PI3K ) and Ral guanine nucleotide-dissociation stimulator ( RALGDS ), to regulate various cellular responses including proliferation, survival and differentiatio”
BackgroundBraun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307203101 · Cited by 299
Self-citationEsteban, L. M., Vicario-Abejón, C., Fernández-Salguero, P., Fernández-Medarde, A., Swaminathan, N., Yienger, K., Lopez, E., Malumbres, M., McKay, R., Ward, J. M., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1444-1452.2001 · Cited by 298 · cited 1×
“By contrast, mice deficient in HRAS and NRAS, both alone or in combination, develop normally and are viable and fertil”
BackgroundDiverse Biochemical Properties of Shp2 Mutants
Keilhack, H., David, F. S., McGregor, M., Cantley, L. C., & Neel, B. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504699200 · Cited by 298 · cited 1×
“The PTPN11 mutations identified in patients with Noonan syndrome are gain-of-function alleles, which encode SHP2 proteins that variably deregulate phosphatase activity, the affinity of the SH2 domains for phosphotyrosyl ligands and/or substrate specificitie”
BackgroundMohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 277
The role of Shp2 (PTPN11) in cancer
Mohi, M. G., & Neel, B. G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.011 · Cited by 274 · cited 1×
“PTPN11 encodes SHP2, an SH2-domain-containing non-receptor tyrosine phosphatase (PTPase) that relays signals from activated growth-factor-receptor complexes to regulate responses such as proliferation, differentiation and migratio”
BackgroundThe cardiofaciocutaneous syndrome
Roberts, A., Allanson, J., Jadico, S. K., Kavamura, M. I., Noonan, J., Opitz, J. M., Young, T., & Neri, G. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.042796 · Cited by 271
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20476 · Cited by 270
An Shp2/SFK/Ras/Erk Signaling Pathway Controls Trophoblast Stem Cell Survival
Yang, W., Klaman, L. D., Chen, B., Araki, T., Harada, H., Thomas, S. M., George, E. L., & Neel, B. G. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.01.002 · Cited by 263 · cited 1×
“SHP2 generally has a positive role in signal transduction, and is required for the full activation of the Ras–Raf–MEK–ERK pathway in most, if not all, cellular context”
BackgroundKing, A. J., Patrick, D. R., Batorsky, R. S., Ho, M. L., Do, H. T., Zhang, S. Y., Kumar, R., Rusnak, D. W., Takle, A. K., Wilson, D. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2554 · Cited by 257 · cited 1×
“Cooperating mutations that enable malignancy are likely to further increase dependence on the BRAF pathway, as chemical inhibitors of BRAF signalling selectively block the proliferation of tumour cell lines with BRAF mutation”
BackgroundThe murine N-ras gene is not essential for growth and development.
Umanoff, H., Edelmann, W., Pellicer, A., & Kucherlapati, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1709 · Cited by 234 · cited 1×
“By contrast, mice deficient in HRAS and NRAS, both alone or in combination, develop normally and are viable and fertil”
BackgroundGenotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases
Kerr, B., Delrue, M.-A., Sigaudy, S., Perveen, R., Marche, M., Burgelin, I., Stef, M., Tang, B., Eden, O. B., O’Sullivan, J., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.040352 · Cited by 231
Shi, Z.-Q., Yu, D.-H., Park, M., Marshall, M., & Feng, G.-S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1526-1536.2000 · Cited by 228 · cited 1×
“SHP2 generally has a positive role in signal transduction, and is required for the full activation of the Ras–Raf–MEK–ERK pathway in most, if not all, cellular context”
BackgroundCarta, C., Pantaleoni, F., Bocchinfuso, G., Stella, L., Vasta, I., Sarkozy, A., Digilio, C., Palleschi, A., Pizzuti, A., Grammatico, P., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/504394 · Cited by 225 · cited 1×
“Ras genes were also considered good candidate disease genes in the ∼50% of patients with Noonan syndrome without PTPN11 mutations, and studies from several laboratories have identified germline mutations in KRAS in 2–4% of affected individual”
BackgroundNguyen, T. T., Scimeca, J. C., Filloux, C., Peraldi, P., Carpentier, J. L., & Van Obberghen, E. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98418-8 · Cited by 224
Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions
Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rütten, A., Mentzel, T., Hügel, H., Hantschke, M., Schmid-Wendtner, M.-H., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12559.x · Cited by 221
Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/– mast cells
Feng-Chun, Y., Ingram, D. A., Chen, S., Hingtgen, C. M., Ratner, N., Monk, K. R., Clegg, T., White, H., Mead, L., Wenning, M. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19195 · Cited by 221 · cited 1×
“Finally, Nf1 inactivation in Schwann cells induces plexiform neurofibromas in mice only in the presence of heterozygous mutant cells in the microenvironmen”
BackgroundGTPase activating proteins: critical regulators of intracellular signaling
Donovan, S., Shannon, K. M., & Bollag, G. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00041-5 · Cited by 215
Self-citationA functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling
Friedman, A., & Perrimon, N. (2006) · Nature · doi:10.1038/nature05280 · Cited by 212 · cited 1×
“Indeed, the contributions of individual proteins to the output of a particular pathway seem to vary in a continuous manner rather than suggesting the existence of one or a few dominant element”
BackgroundExpansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations
Zenker, M., Lehmann, K., Schulz, A. L., Barth, H., Hansmann, D., Koenig, R., Korinthenberg, R., Kreiss-Nachtsheim, M., Meinecke, P., Morlot, S., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.046300 · Cited by 202 · cited 1×
“Ras genes were also considered good candidate disease genes in the ∼50% of patients with Noonan syndrome without PTPN11 mutations, and studies from several laboratories have identified germline mutations in KRAS in 2–4% of affected individual”
BackgroundJohn, J., Frech, M., & Wittinghofer, A. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37854-2 · Cited by 201
Differential Modification of Ras Proteins by Ubiquitination
Jura, N., Scotto-Lavino, E., Sobczyk, A., & Bar-Sagi, D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.011 · Cited by 196 · cited 1×
“Ras isoforms are also differentially ubiquitylated, which might modulate signalling propertie”
BackgroundHRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation
Gripp, K. W., Lin, A. E., Stabley, D. L., Nicholson, L., Scott, C. I., Doyle, D., Aoki, Y., Matsubara, Y., Zackai, E. H., Lapunzina, P., et al. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31047 · Cited by 191
Stops along the RAS pathway in human genetic disease
Bentires-Alj, M., Kontaridis, M. I., & Neel, B. G. (2006) · Nature Medicine · doi:10.1038/nm0306-283 · Cited by 190 · cited 1×
“The developmental disorders associated with Ras pathway mutations share phenotypic features that include facial abnormalities, heart defects, impaired growth and development, and, in some instances, a predisposition to specific cancer”
BackgroundThe effector interactions of p21ras
Marshall, M. S. (1993) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(93)90175-m · Cited by 189
Sansom, O. J., Meniel, V., Wilkins, J. A., Cole, A. M., Oien, K. A., Marsh, V., Jamieson, T. J., Guerra, C., Ashton, G. H., Barbacid, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604130103 · Cited by 187 · cited 1×
“However, oncogenic Kras accelerated intestinal tumorigenesis in mice that also carried a mutant allele of the adenomatous polyposis coli ( Apc ) tumour-suppressor gen”
BackgroundRalGDS is required for tumor formation in a model of skin carcinogenesis
González-García, A., Pritchard, C. A., Paterson, H. F., Mavria, G., Stamp, G., & Marshall, C. J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.029 · Cited by 181
Ingram, D. A., Yang, F.-C., Travers, J. B., Wenning, M. J., Hiatt, K., New, S., Hood, A., Shannon, K., Williams, D. A., & Clapp, D. W. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.1.181 · Cited by 181 · cited 1×
“Haploinsufficiency appears to play an important role in common NF1-associated developmental phenotypes such as macrocephaly and learning disabilities, and heterozygous inactivation of murine Nf1 has biochemical and phenotypic consequences in mast cells and melanocytes , two cell types that frequently demonstrate abnor…”
BackgroundSelf-citationEstep, A. L., Tidyman, W. E., Teitell, M. A., Cotter, P. D., & Rauen, K. A. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31078 · Cited by 180
Ras caught in another affair: the exchange factors for Ral
Wolthuis, R. M. F., & Bos, J. L. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80016-1 · Cited by 180 · cited 1×
“Ras can also activate a family of exchange factors for the Ral small GTPases, which include RALGDS, RALGDS-like gene ( RGL ) and RGL2 (Ref”
BackgroundLe, D. T., Kong, N., Zhu, Y., Lauchle, J. O., Aiyigari, A., Braun, B. S., Wang, E., Kogan, S. C., Le Beau, M. M., Parada, L., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2650 · Cited by 175
Self-citationHanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K., & Nishida, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312498200 · Cited by 174
Ren, Y., Meng, S., Mei, L., Zhao, Z. J., Jove, R., & Wu, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312575200 · Cited by 171 · cited 1×
“Finally, the inactivation of the negative regulatory CSK pathway has also been proposed to mediate SHP2-dependent Ras activatio”
BackgroundGenetic Screening for Signal Transduction in the Era of Network Biology
Friedman, A. A., & Perrimon, N. (2007) · Cell · doi:10.1016/j.cell.2007.01.007 · Cited by 171 · cited 1×
“Data from diverse sources such as unbiased genetic screens in yeast, animal models, experiments in which cultured cells or genetically engineered mice were exposed to inhibitors of signalling molecules, and human clinical trials have uncovered unexpected complexity and adaptation in signalling network”
BackgroundFunctional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
Schubbert, S., Lieuw, K. H., Rowe, S. L., Lee, C. M., Li, X., Loh, M. L., Clapp, D. W., & Shannon, K. (2005) · Blood · doi:10.1182/blood-2004-11-4207 · Cited by 159
Self-citationIdentification of a Putative Syp Substrate, the PDGFβ Receptor
Klinghoffer, R. A., & Kazlauskas, A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22208 · Cited by 157
Neurofibromatosis Type 1 Due to Germ-Line Mosaicism in a Clinically Normal Father
Lázaro, C., Ravella, A., Gaona, A., Volpini, V., & Estivill, X. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312102 · Cited by 147 · cited 1×
“NF1 is a dominant familial cancer syndrome with an incidence of approximately 1 in 3,500 (Ref”
BackgroundThe beta-PDGF receptor induces neuronal differentiation of PC12 cells.
Heasley, L. E., & Johnson, G. L. (1992) · Molecular Biology of the Cell · doi:10.1091/mbc.3.5.545 · Cited by 145
Zampino, G., Pantaleoni, F., Carta, C., Cobellis, G., Vasta, I., Neri, C., Pogna, E. A., Feo, E. D., Delogu, A. B., Sárközy, A., et al. (2006) · Human Mutation · doi:10.1002/humu.20431 · Cited by 134
Kinetic analysis of the hydrolysis of GTP by p21N-ras. The basal GTPase mechanism.
Neal, S. E., Eccleston, J. F., Hall, A., & Webb, M. R. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77694-7 · Cited by 130
Matallanas, D., Sanz-Moreno, V., Arozarena, I., Calvo, F., Agudo-Ibáñez, L., Santos, E., Berciano, M., & Crespo, P. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.100-116.2006 · Cited by 130
Identification of PLC210, a Caenorhabditis elegansPhospholipase C, as a Putative Effector of Ras
Shibatohge, M., Kariya, K., Liao, Y., Hu, C., Watari, Y., Goshima, M., Shima, F., & Kataoka, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6218 · Cited by 127 · cited 1×
“Phospholipase Ce also binds directly to Ras–GTP, and the consequent hydrolysis of PIP2 to diacylglycerol and inositol-1,4,5-triphosphate serves to release calcium and activate protein kinase”
BackgroundRas signaling from plasma membrane and endomembrane microdomains
Plowman, S. J., & Hancock, J. F. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2005.06.004 · Cited by 124 · cited 1×
“A significant portion of NRAS and HRAS reside in the Golgi, and studies have shown that these proteins can signal on this organelle as well as on other endomembrane compartments, such as the endoplasmic reticulu”
BackgroundGuanine nucleotides, protein phosphorylation and the control of translation
Proud, C. G. (1986) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(86)90269-0 · Cited by 124
Frearson, J. A., & Alexander, D. R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1417 · Cited by 123 · cited 1×
“SHP2 generally has a positive role in signal transduction, and is required for the full activation of the Ras–Raf–MEK–ERK pathway in most, if not all, cellular context”
BackgroundRole of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response
Qu, C. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00322-1 · Cited by 120 · cited 1×
“PTPN11 encodes SHP2, an SH2-domain-containing non-receptor tyrosine phosphatase (PTPase) that relays signals from activated growth-factor-receptor complexes to regulate responses such as proliferation, differentiation and migratio”
BackgroundSHP-2 and myeloid malignancies
Tartaglia, M., Niemeyer, C. M., Shannon, K., & Loh, M. L. (2003) · Current Opinion in Hematology · doi:10.1097/00062752-200401000-00007 · Cited by 118
Self-citationReduced phosphatase activity of SHP‐2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1
Hanna, N., Montagner, A., Lee, W. H., Miteva, M. A., Vidal, M., Vidaud, M., Parfait, B., & Raynal, P. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.088 · Cited by 117
Muroya, K., Hattori, S., & Nakamura, S. (1992) · PubMed · Cited by 100
Augsten, M., Pusch, R., Biskup, C., Rennert, K., Wittig, U., Beyer, K., Blume, A., Wetzker, R., Friedrich, K., & Rubio, I. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400560 · Cited by 99 · cited 1×
“A recent study using a probe targeted to endogenous Ras–GTP suggests that the plasma membrane is the predominant site of growth-factor-induced activation of Ra”
BackgroundInherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
Self-citationCleghon, V., Feldmann, P., Ghiglione, C., Copeland, T. D., Perrimon, N., Hughes, D. A., & Morrison, D. K. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80287-7 · Cited by 92 · cited 1×
“One involves a p120GAP docking site on growth-factor receptors or adaptors such as Gab; by dephosphorylating such sites, SHP2 prevents the membrane localization of p120GAP, therefore preventing the downregulation of Ra”
BackgroundFranken, S. M., Scheidig, A. J., Krengel, U., Rensland, H., Lautwein, A., Geyer, M., Scheffzek, K., Goody, R. S., & Kalbitzer, H. R. (1993) · Biochemistry · doi:10.1021/bi00084a005 · Cited by 91 · cited 1×
“Substituting proline for glycine 12 renders Ras resistant to GAPs, but has increased intrinsic GTP hydrolysi”
BackgroundRas redux: rethinking how and where Ras acts
Hingorani, S. R., & Tuveson, D. A. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00017-5 · Cited by 88
Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases
Jarvis, L. A., Peters, S. T., Simon, M. A., Krasnow, M. A., & Smith-Bolton, R. K. (2006) · Development · doi:10.1242/dev.02255 · Cited by 86 · cited 1×
“By inactivating this negative regulator, SHP2 would have a generalized positive effect on growth–factor-dependent signallin”
BackgroundEpidemiology of neurofibromatosis type 1 (NF1) in northern Finland
Pöyhönen, M., KYTÖLÄ, S., & LEISTI, J. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.8.632 · Cited by 73
Involvement of SHP-2 in multiple aspects of IL-2 signaling: evidence for a positive regulatory role.
Gadina, M., Stancato, L. M., Bacon, C. M., Larner, A. C., & O’Shea, J. J. (1998) · PubMed · Cited by 72
Gadina, M., Stancato, L. M., Bacon, C. M., Larner, A. C., & O’Shea, J. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.4657 · Cited by 63
Prelude to an Anniversary for the RAS Oncogene
Downward, J. (2006) · Science · doi:10.1126/science.1134727 · Cited by 49
Biochemical Characterization of Polypeptides Encoded by Mutated Human Ha-ras1 Genes
Colby, W. W., Hayflick, J. S., Clark, S. G., & Levinson, A. D. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.2.730 · Cited by 47
Quilliam, L. A., Zhong, S., Rabun, K. M., Carpenter, J. W., South, T. L., Der, C. J., & Campbell, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1272 · Cited by 41 · cited 1×
“Although in-depth biochemical analysis of the V152G and D153V KRAS mutants has not yet been reported, an F156L substitution in HRAS results in a rapid rate of nucleotide dissociation, modestly increases Ras–GTP levels, and transforms rodent fibroblast”
BackgroundK-Ras is essential for normal fetal liver erythropoiesis.
Khalaf, W., White, H. A., Wenning, M., Orazi, A., Kapur, R., & Ingram, D. A. (2005) · Blood · doi:10.1182/blood-2004-05-2021 · Cited by 36 · cited 1×
“KRAS-deficient mice die of anaemia and defective fetal liver erythropoiesis after about 12–14 days of gestatio”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
RNA-binding proteins in human genetic disease
Gebauer, F., Schwarzl, T., Valcárcel, J., & Hentze, M. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00302-y · Cited by 1,176
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.